E C Borden
Overview
Explore the profile of E C Borden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
3563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chawla-Sarkar M, Leaman D, Borden E
Clin Cancer Res
. 2001 Jun;
7(6):1821-31.
PMID: 11410525
On the basis of in vitro inhibition of tumor cell growth, IFNs have been generally considered to be antiproliferative proteins. To probe further the potential mechanisms of the antitumor effects...
12.
Borden E
Semin Oncol
. 2000 Dec;
27(6):654-6.
PMID: 11130472
The only consistent factor influencing prognosis of primary melanoma in pregnancy has been the stage of disease at diagnosis, not the pregnancy. However, several studies suggest that pregnant women may...
13.
14.
Borden E, Lindner D, Dreicer R, Hussein M, Peereboom D
Semin Cancer Biol
. 2000 Aug;
10(2):125-44.
PMID: 10936063
IFNs were the first new therapeutic products resulting from recombinant DNA technology. IFNs were also the first human proteins effective in cancer treatment. There is however much to be discovered...
15.
Walter M, Bordens R, Nagabhushan T, Williams B, Herberman R, Dinarello C, et al.
Cancer Biother Radiopharm
. 2000 Jun;
13(3):143-54.
PMID: 10850350
Recombinant alfa interferons (IFN-alpha s) are approved worldwide for the treatment of a variety of cancers and diseases of virologic origin. A series of recent advances in the molecular characterization...
16.
Borden E, Esserman L, Linder D, Campbell M, FULTON A
Semin Oncol
. 1999 Sep;
26(4 Suppl 12):28-40.
PMID: 10482192
Systemic treatments for breast carcinoma have improved substantially over the past quarter century. New insights into cancer biology, refinements in biotechnology, and bioengineering of macromolecules hold the promise of even...
17.
Rosenthal M, Green M, Wiernik P, Borden E, Marsh J, Haller D
Am J Clin Oncol
. 1998 Oct;
21(5):509-12.
PMID: 9781611
Epirubicin (4'-epidoxorubicin), a diastereoisomer of doxorubicin, has established activity in the treatment of many cancer types sensitive to doxorubicin. Its activity in other tumor targets such as melanoma, head and...
18.
Pfeffer L, Dinarello C, Herberman R, Williams B, Borden E, Bordens R, et al.
Cancer Res
. 1998 Jul;
58(12):2489-99.
PMID: 9635566
IFNs were first described as potent antiviral agents 40 years ago, and recombinant IFN-alpha2a and IFN-alpha2b were approved for the treatment of hairy cell leukemia just 11 years ago. Today,...
19.
20.
Borden E, Parkinson D
Semin Oncol
. 1998 Mar;
25(1 Suppl 1):3-8.
PMID: 9482534
Interferons (IFNs) are potent biologic response modifiers with antiviral and antiproliferative effects. The successful clinical application of IFNs for the treatment of chronic viral infections and malignancies has resulted in...